Western University of Health Sciences
Trial Pipeline
ImmunoBoost: The Lymphatic Osteopathic Manipulative Treatment Protocol Study
NCT06565065
Tracking Post-stroke Walking Improvements From the Clinic Into the Home
NCT05454007
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
NCT05763940
Assessment of Three Basic Progressive Lens Designs
NCT05252871
Augmentation of Immune Response to COVID-19 mRNA Vaccination Through OMT With Lymphatic Pumps
NCT04928456
Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
NCT03174366
Effect of Osteopathic Manipulative Treatment for Patients With Chronic Headache
NCT01332864
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for Western University of Health Sciences Shows
According to the ClinicalTrials.gov registry, Western University of Health Sciences is linked to 7 US clinical trials across every stage of research activity. Of those, 2 studies are currently recruiting — about 29% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 57% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Western University of Health Sciences reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Western University of Health Sciences is Cephalgia with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.